Summary of Praxis Precision Medicines (PRAX) Fireside Chat - August 07, 2025 Company Overview - **Company**: Praxis Precision Medicines (PRAX) - **Focus**: Development of therapies for epilepsy, specifically the drug rometragene Key Industry Insights - **Market Size**: Approximately 3 million patients with epilepsy, with over 60% unable to tolerate or respond to current treatments, indicating a significant unmet need in the epilepsy market [10][11] - **Drug Efficacy**: The drug has shown promising results in treating refractory epilepsy, with a notable response rate in difficult-to-treat patients [9][12] Core Points Discussed 1. **Phase One Data**: Initial phase one data did not provide clear differentiation for rometragene compared to other therapies, but subsequent data has shown significant promise [3][6] 2. **RADIANT Study**: The RADIANT study involved 61 patients as of July 25, with a target of 75 patients. The study aims to provide data on both generalized and focal epilepsy patients [13][15] 3. **Patient Response**: The drug has demonstrated a high response rate, with 100% of patients responding in earlier studies, although translating this to broader patient populations remains complex [8][9] 4. **Discontinuation Rates**: The discontinuation rate reported was 23%, primarily occurring within the first three weeks of treatment. This is considered acceptable given the severity of the patient population [36][37] 5. **Safety and Efficacy**: The pharmacokinetics (PK) of rometragene in patients were comparable to healthy volunteers, and the drug did not adversely affect safety or discontinuation rates [22][34] 6. **Seizure Reduction**: The total seizure reduction was reported at 56%, with potential for up to 70% reduction by week eight. The drug's efficacy appears to improve over time [66][72] Additional Considerations - **Patient Recruitment**: The study has faced challenges in patient recruitment due to the complexity of screening and the nature of the patient population [80][81] - **Open Label Data**: Concerns regarding the validity of open-label data were addressed, emphasizing that treatment effects are consistent regardless of whether patients are aware of their treatment status [83][89] - **Future Expectations**: The company anticipates that longer treatment durations will lead to improved outcomes, with ongoing studies expected to confirm these trends [68][72] Conclusion Praxis Precision Medicines is positioned in a significant market with a promising drug candidate for epilepsy. The insights from the RADIANT study and ongoing trials suggest a strong potential for rometragene to address unmet needs in the epilepsy treatment landscape. The company is focused on refining its approach to patient recruitment and data collection to ensure robust outcomes in future studies.

Summary of ReGen III Conference Call - August 07, 2025 Company Overview - **Company Name**: ReGen III - **Ticker Symbols**: ISRJF (OTCQB), GIII (TSXV) - **Industry**: Cleantech, specifically focusing on the production of lubricating base oils from used motor oil Core Points and Arguments 1. **Business Model**: ReGen III transforms used motor oil into premium Group II+ and Group III base oils, addressing a growing supply-constrained global market [4][6][11] 2. **Market Demand**: There is a rising demand for Group III base oils, which are considered the gold standard in performance lubricants, while supply remains limited and heavily reliant on imports [5][18] 3. **Cost Efficiency**: The company claims to produce Group III base oils at significantly lower costs than virgin producers, providing exceptional margins and a sustainable competitive edge [6][10][33] 4. **Environmental Impact**: ReGen III's process is positioned as a circular economy solution, converting hazardous waste into high-value products, thus reducing environmental harm [11][22][46] 5. **Market Opportunity**: The global demand for Group III base oils is expected to double by 2050, with only 1-2% of current supply coming from re-refined sources, indicating a significant market gap [26][47] 6. **Strategic Partnerships**: The company is in advanced discussions with major oil companies and global blenders for strategic partnerships and offtake agreements, indicating strong market interest [16][36] 7. **Texas City Project**: The flagship project in Texas City aims to be the largest re-refined Group III facility in North America, with a capacity of 5,600 barrels per day [39][42] 8. **Feedstock Supply**: ReGen III has secured letters of intent for over half of the required feedstock for its Texas City facility, ensuring supply stability [57] 9. **Regulatory Alignment**: The company’s operations align with the push for clean energy and domestic manufacturing in both the US and Canada [37][48] Additional Important Content 1. **Leadership Experience**: CEO Tony Weatherill has over 35 years of experience in the oil and petrochemical industry, enhancing the company's credibility [12][13] 2. **Technological Edge**: The company holds 32 global patents for its proprietary process, providing a defensible position in a market demanding change [15] 3. **Market Positioning**: ReGen III is not just competing on cost but is focused on delivering a premium product that commands a price premium of 40-50% over Group II and Group I oils [18][29] 4. **Future Expansion Plans**: The company plans to target multiple follow-on projects across the US, Europe, Asia Pacific, and the Middle East, indicating a roadmap for global expansion [47][54] 5. **Investor Opportunity**: The current market cap of $30 million Canadian is viewed as a disconnect from the company's potential, presenting an opportunity for early investors [49][51] This summary encapsulates the key insights from the ReGen III conference call, highlighting the company's innovative approach, market potential, and strategic initiatives.

Summary of Electro Optic Systems Holdings (EOS) Update / Briefing Company Overview - **Company**: Electro Optic Systems Holdings (EOS) - **Industry**: Defense and Aerospace, specifically focusing on high energy laser weapons for counter-drone applications Key Points and Arguments New Contract Announcement - EOS announced a new contract for a **100 kilowatt high energy laser weapon** for counter-drone usage, valued at **125 million Australian dollars** with a NATO country [5][6][62] - This contract marks a historic moment as it is the first time a **100 kilowatt laser weapon** will be operational in the battlefield [5][6] Market Need and Characteristics - The need for anti-drone warfare has escalated, particularly highlighted by the Ukraine conflict, where over **70%** of armored vehicles are targeted by drones [6][12] - The current drone threat includes **commercial drones** that can be produced at low costs, making them difficult to counter with traditional methods [11][12] Product Capabilities - The **100 kilowatt laser weapon** can effectively defeat **over 95%** of drone attacks, including class two drones like the Shahid drone [15][30] - The system is designed for **multilayered air defense**, combining soft kill and hard kill effectors, including kinetic systems and lasers [7][8][27] Cost Efficiency - The cost per kill with the laser weapon is estimated to be between **1 and 10 USD**, making it significantly more affordable compared to traditional missile systems, which can cost between **500,000 and 2,000,000 USD** per shot [19][18][34] Production and Scalability - EOS plans to establish production facilities in client countries, funded by the clients, allowing for localized production and IP transfer [71][72] - The Singapore facility can handle multiple projects simultaneously, with potential for expansion [83] Competitive Landscape - EOS faces limited competition, primarily from an Israeli consortium offering similar products, but EOS holds a strategic advantage due to its IP ownership and export capabilities [40][41][46] - The company is positioned to dominate the anti-drone market, with expectations of significant revenue growth in the coming years [39][46] Financial Outlook - The contract is expected to generate revenue primarily in **2026 and 2027**, with a gross margin of around **50%** on materials [62][63] - The project is designed to be cash flow neutral in its initial phase, with no significant capital investment required from EOS [65] Future Growth Opportunities - EOS anticipates further orders from clients looking to protect military and civilian infrastructure, with potential for over **100 systems** to be ordered by two clients over the next decade [67][68] - The company is optimistic about the growth of its business segment, particularly in counter-drone and space control markets [75][76] Additional Important Information - The laser weapon system is modular and can be scaled from **50 to 150 kilowatts**, allowing for adaptability to various threats [48][30] - The technology is designed to operate effectively in harsh environments, providing a competitive edge in military applications [48] - EOS has plans for ongoing demonstrations to showcase the effectiveness of its systems to potential clients [50][49] This summary encapsulates the critical aspects of the EOS briefing, highlighting the company's strategic positioning, product capabilities, market dynamics, and financial outlook.

Summary of Eledon Pharmaceuticals (ELDN) Update / Briefing August 06, 2025 Company Overview - **Company**: Eledon Pharmaceuticals (ELDN) - **Focus**: Development of tegoprovart for kidney transplantation Key Industry Insights - **Industry**: Kidney transplantation and immunosuppression therapies - **Event**: Presentation of updated Phase 1b trial results at the World Transplant Congress Core Points and Arguments 1. **Phase 1b Trial Results**: Eledon presented updated results from the Phase 1b trial of tegoprovart, which is being evaluated as a cornerstone immunosuppression therapy in de novo kidney transplantation [3][6][8] 2. **Safety and Efficacy**: The trial demonstrated good safety and tolerability for tegoprovart, with twelve-month eGFR (estimated Glomerular Filtration Rate) results indicating good kidney function [8][26] 3. **Rejection Episodes**: A total of six rejection episodes were reported, with a 19% incidence rate. Most rejections occurred in patients receiving lower doses of ATG (antithymocyte globulin) induction therapy [21][24] 4. **Long-term Predictive Endpoints**: The trial included the abbreviated IBOX score, which is being developed as a surrogate endpoint to predict five-year graft survival. The IBOX score showed strong predictive capabilities [31][35] 5. **Regulatory Considerations**: Eledon is in discussions with regulatory bodies regarding the use of IBOX as a potential endpoint for future clinical trials, with expectations for feedback in the second half of the following year [31][59] Additional Important Content 1. **Patient Demographics**: The study included 32 patients with a mean age of 52.9 years, with 75% being living donors. Notably, 56% of patients had an HLA mismatch of more than five, indicating a higher immunological risk [15][16][94] 2. **Infection Rates**: The trial reported manageable infection rates, with no cases of graft loss. The infections were controllable, and the study aims to explore lower dosing to potentially improve safety outcomes [90][91] 3. **Impact of Improved Graft Survival**: A hypothetical 5% improvement in five-year graft survival could significantly reduce the number of patients dying while waiting for a kidney transplant, potentially allowing for 1,500 additional kidneys to be available each year [41][43] 4. **Future Studies**: Eledon is preparing for the Phase II BISTOLE study, with results expected to be presented in the fourth quarter of the year [44] Conclusion Eledon Pharmaceuticals is making significant strides in the development of tegoprovart for kidney transplantation, with promising Phase 1b trial results indicating good safety and efficacy. The company is focused on regulatory discussions regarding the IBOX score as a predictive endpoint for long-term graft survival, which could have a substantial impact on patient outcomes in the field of kidney transplantation.

Summary of Expeditors International of Washington (EXPD) Update / Briefing August 06, 2025 Industry Overview - The briefing focuses on the U.S. Customs market and recent trade actions affecting importers, particularly in relation to tariffs and trade agreements [6][7][8]. Key Points and Arguments 1. **Recent U.S. Trade Actions**: - Six major trade actions are highlighted, with specific dates for implementation [7]. - Notable actions include the increase of tariffs on fentanyl imports from Canada and the introduction of copper tariffs from Brazil [10][11][12]. 2. **Tariff Increases**: - Fentanyl tariffs from Canada increased from 25% to 35% [13]. - Copper tariffs from Brazil set at 40%, raising the total tariff to 50% when combined with existing rates [25][26]. 3. **Reciprocal Tariffs**: - A new set of reciprocal tariffs will be implemented affecting 95 countries, with rates changing from a universal 10% to new specific rates [30][34]. - Countries with trade deficits with the U.S. may see increases in tariffs ranging from 15% to 41% [34]. 4. **In-Transit Exemptions**: - Exemptions for goods loaded on vessels before specific deadlines to avoid additional tariffs [26][56]. - Documentation is emphasized as crucial for claiming these exemptions [28][29]. 5. **Impact on India**: - An additional 25% duty on imports from India starting August 27, raising the total tariff to 50% due to geopolitical tensions [54][55]. 6. **End of De Minimis**: - The end of de minimis for low-value shipments (under $800) will apply to all countries starting August 29, requiring formal entries for all imports [59][62]. 7. **Ongoing Investigations**: - Section 232 investigations are ongoing, focusing on national security risks related to various industries, including pharmaceuticals and semiconductors [68][69]. 8. **Legal Challenges**: - Legal challenges against the government's authority to impose tariffs under the International Emergency Economic Powers Act (IEPA) are ongoing, with potential implications for future tariff enforcement [73][74][78]. 9. **Transshipment Concerns**: - The administration is concerned about transshipment practices that may evade tariffs, particularly involving inputs from non-market economies like China [82][90]. 10. **Value Chain Understanding**: - Importers are encouraged to understand the full value chain of their goods to comply with new regulations and avoid penalties [94][96]. Other Important Content - **Documentation and Compliance**: Emphasis on the importance of maintaining accurate documentation for customs declarations and understanding the life cycle of customs entries [99][100]. - **Future Outlook**: Continued monitoring of trade actions and legal developments is advised, as changes are expected to impact various sectors significantly [71][72]. This summary encapsulates the critical updates and insights from the Expeditors International briefing, focusing on the evolving landscape of U.S. trade policies and their implications for importers.

Summary of AMD Conference Call Company Overview - **Company**: AMD (Advanced Micro Devices) - **Quarter**: Q2 2025 - **Revenue**: $7.7 billion, a record high, up 32% year-over-year [2][3][22] Key Points Financial Performance - **Revenue Growth**: Achieved a record revenue of $7.7 billion, driven by strong sales in EPYC processors and data center business [2][3][22] - **Gross Margin**: Reported a gross margin of 54%, marking the sixth consecutive quarter of year-over-year gross margin expansion [3][22] - **Free Cash Flow**: Generated over $1 billion in free cash flow [3] - **Operating Income**: $897 million, representing 12% of revenue [22] Data Center Business - **Revenue**: Data center revenue grew 14% year-over-year to $3.2 billion, despite a $155 million operating loss due to MI308 export restrictions [2][5][23] - **AI Business**: The data center AI segment faced challenges due to export restrictions, but MI300 and MI325 series products showed good progress with new contracts signed [10][4] - **EPYC Demand**: Strong demand for EPYC processors, particularly in cloud computing and enterprise workloads [5][23] Client and Gaming Segments - **Client Revenue**: Client segment revenue reached $2.5 billion, up 67% year-over-year, driven by record desktop CPU sales [17][25] - **Gaming Revenue**: Gaming segment revenue increased 73% to $1.1 billion, supported by strong demand for custom chips for next-gen consoles and new GPU launches [19][24] Future Outlook - **Q3 2025 Revenue Guidance**: Expected revenue of approximately $8.7 billion, a year-over-year increase of about 28% [4][29] - **Product Development**: Actively developing the next-generation MI400 series GPUs, expected to deliver up to 40 petaflops of AI computing power [4][13] - **Helios Platform**: Introduction of Helios, a full-stack AI platform expected to provide a tenfold performance leap for advanced models [14] Market Dynamics - **Telecom Sector**: KDDI and Nokia are deploying EPYC processors for 5G networks, enhancing AMD's presence in the telecom industry [6] - **Embedded Business**: Revenue declined 4% to $824 million, but demand is gradually recovering [20][26] Strategic Initiatives - **Acquisitions**: Completed the acquisition of ZT Systems and announced the divestiture of ZT manufacturing business [27][47] - **Cash Management**: Generated $1.5 billion in cash from operations, with a total cash and short-term investments of $5.9 billion [28] Regulatory Challenges - **Export Licenses**: Working with the U.S. Department of Commerce to secure MI308 export licenses to China, with ongoing reviews impacting revenue guidance [16][31] Competitive Position - **High-Performance Computing**: AMD powers over one-third of the world's fastest supercomputers, showcasing its performance and efficiency advantages [9][10] AI and Software Developments - **Rockem Software**: Significant improvements in performance and usability, with the latest version showing over threefold increases in inference and training performance [11][12] Additional Insights - **Market Share**: Positive outlook on server CPU market share growth, particularly in traditional enterprise servers [44] - **Customer Engagement**: Strong interest from customers in MI400 and Helios platforms, indicating a robust pipeline for future growth [38][42] This summary encapsulates the key insights and developments from AMD's recent conference call, highlighting the company's strong financial performance, strategic initiatives, and future outlook in the competitive landscape.

Summary of Expeditors International of Washington (EXPD) Update / Briefing Company Overview - **Company**: Expeditors International of Washington (EXPD) - **Division**: Onyx, an advisory firm under Expeditors, focuses on global supply chains and navigating trade disruptions [8][10] Industry Context - **Industry**: Trade and logistics, with a focus on customs and tariffs - **Current Environment**: Significant changes in U.S. trade policy, particularly regarding tariffs and trade agreements with various countries [13][15] Key Points and Arguments 1. **Tariff Changes**: Nine new tariff levels were announced, increasing the overall effective tariff rate significantly, with a focus on transshipment, which incurs an additional 40% tariff for goods attempting to avoid tariffs [15][16] 2. **Focus on China**: The U.S. administration is primarily targeting Chinese goods and exports, with a notable removal of de minimis exemptions for goods valued at $800 or less [17][18] 3. **Impact of Tariffs**: The competitive landscape will be affected on an industry-by-industry and product-by-product basis, with ongoing evaluations of how these tariffs will impact various sectors [20][21] 4. **Uncertainty in Trade Deals**: Current agreements are not fully defined, leading to significant uncertainty in trade relationships, particularly with the EU, Canada, and Mexico [22][56] 5. **Political Pressures**: Domestic political pressures, especially with upcoming midterms, may influence tariff policies and negotiations [26][66] 6. **EU Relations**: The EU has avoided a full trade war with the U.S., but faces economic and political challenges due to the current tariff landscape [27][58] 7. **China-U.S. Relations**: The relationship is in a strategic pause, with limited deals expected, focusing on structural demands rather than comprehensive agreements [62][63] 8. **USMCA and India**: The USMCA remains unresolved, and the Trump administration is applying pressure on India with reciprocal tariffs and potential sanctions related to oil purchases from Russia [66][70] Additional Important Insights 1. **Macroeconomic Impact**: Tariffs are expected to have a stagflationary effect, negatively impacting growth while pushing inflation higher, with estimates of a half percentage point reduction in GDP growth [80][81] 2. **Sector-Specific Effects**: Consumer electronics, automobiles, and industrial metals are among the most affected sectors due to high tariff exposure [82] 3. **Fiscal Implications**: Tariffs are projected to generate significant revenue, but the regressive nature of tariffs may disproportionately affect lower-income households [86] 4. **Investment Trends**: There is a potential shift in foreign direct investment towards Mexico and ASEAN economies as companies seek to derisk from China [87] Conclusion - The current trade environment is characterized by significant uncertainty and evolving tariff policies, with potential long-term implications for various sectors and international relationships. The focus remains on navigating these changes while assessing their macroeconomic impacts and sector-specific challenges.

Summary of Gold Road Resources Conference Call Company Overview - **Company**: Gold Road Resources - **Industry**: Mining, specifically gold mining Key Points and Arguments 1. **Acquisition by Goldfields**: Gold Road entered a binding scheme of arrangement with Goldfields on May 4, under which Goldfields will acquire 100% of Gold Road. The offer represents a 20% premium to Gold Road's share price prior to the approach and is 12% higher than Goldfields' initial proposal [3][4] 2. **Shareholder Recommendations**: The Gold Road Board unanimously recommends that shareholders vote in favor of the scheme, pending no superior proposals and the independent expert's conclusion that the scheme is in shareholders' best interest [4] 3. **Dividend Declaration**: Gold Road intends to declare a fully franked dividend of $0.35 per share if the scheme becomes effective, with the final amount dependent on the franking credit account balance at that time [4][5] 4. **Regulatory Process**: The scheme involves an intensive process, including drafting key documents and obtaining regulatory approvals. The first court hearing is anticipated in mid-August, with the scheme meeting and second court hearing likely in late September [5][7] 5. **Share Price Performance**: Since the offer became public, Gold Road's share price has closely tracked the implied offer price from Goldfields, indicating market confidence in the transaction's closure [8][9] 6. **Operational Performance**: Current operational performance has been disappointing, with production costs at the lower end of guidance and costs at the upper end. This may have influenced shareholder interest in the acquisition [9] 7. **Value Creation History**: Gold Road has created significant value through discoveries like Gruyere and investments in De Grey, with total investments into De Grey around $400 million, now valued at double that amount [13] 8. **Future Exploration**: Gold Road is conducting a $10 million drill program at Gilmore, aiming to upgrade inferred resources and explore further potential [17] 9. **Underground Mining Potential**: A conceptual study suggests that underground mining at Gruyere is viable, with the potential for high tonnage, low-cost methods like sublevel caving [20][21] 10. **Community Impact**: The acquisition is expected to benefit local communities and native title holders, with Gold Road expressing pride in the value created for shareholders and the potential for future wealth generation [22] Additional Important Content - **Employee Concerns**: The acquisition raises concerns for Gold Road employees regarding job security, with many realistic about the nature of takeovers [23] - **Leadership Transition**: The CEO expressed commitment to supporting employees in finding future opportunities, highlighting the loyalty within the team [24]

Summary of Black Cat Syndicate (BC8) 2025 Conference Company Overview - **Company**: Black Cat Syndicate (BC8) - **Industry**: Gold Mining - **Status**: Transitioned to gold producer status in recent years, with production starting within the last twelve months [4][3] Key Points and Arguments - **Production Goals**: Targeting a run rate of 100,000 ounces per annum by the end of the calendar year, with aspirations to reach 200,000 ounces in the near term [4][7] - **Current Operations**: Two producing assets, Cal East and Paulsens, with production ramping up significantly [4][15] - **Financial Position**: As of June, the company holds cash and listed investments of approximately $56 million, with no debt and zero hedging [7][34] - **Market Capitalization**: Current share price indicates a market cap of around $600 million, with 708 million shares on the market [10][9] - **Board and Management**: Strong management team with extensive experience in the mining sector, including founding directors from Silver Lake Resources [11][10] Production and Operations - **Recent Growth**: Achieved a 33% quarter-on-quarter growth between March and June, with expectations for continued growth [6][25] - **Acquisition of Lakewood Processing Facility**: Acquired a 1,200,000 tonne per annum processing plant, which has already started production and is expected to significantly enhance output [17][18] - **Production Metrics**: Produced 12,000 ounces from the Lakewood facility and an additional 5,000 ounces for third parties in the last quarter [19][25] - **Future Plans**: Plans to ramp up production through new underground and open pit operations, with a focus on optimizing resources [20][23] Exploration and Growth Potential - **Exploration Projects**: Active drilling programs planned for existing projects, including high-grade resources in the Coyote project and potential for significant antimony production [28][30] - **Antimony Project**: The Mount Clement project is highlighted for its high-grade antimony resources, with exploration targets suggesting potential for 100,000 tonnes of antimony [32][31] - **Long-term Vision**: Aiming for organic growth through exploration and development of additional projects, while maintaining a focus on gold production [33][34] Market Environment - **Gold Price Correlation**: The company's share price is closely linked to gold prices, with a strategy to hold gold as a liquid asset in the current high-price environment [8][12] - **Operational Efficiency**: Plans to upgrade processing facilities to increase throughput by 20% to 30%, ensuring a steady supply of processed gold [23][22] Conclusion - **Investment Opportunity**: Black Cat Syndicate presents a compelling investment opportunity with a strong balance sheet, no debt, and a clear path to increased gold production [34][34] - **Future Outlook**: The company is well-positioned for growth in the gold mining sector, with multiple projects and a robust operational strategy [33][34]

Summary of Southern Cross Gold Consolidated Conference Call Company Overview - **Company**: Southern Cross Gold Consolidated (MWSN.D) - **Focus**: High-grade gold and antimony exploration in Victoria, Australia - **Leadership**: Michael Hudson, President and CEO, has extensive experience in mining and has raised over $500 million for mining companies [1][2] Industry Insights - **Geological Renaissance**: Victoria is experiencing a resurgence in mining due to new geological insights and government support, contrasting with historical perceptions of the region [4][6] - **Comparison with Western Australia**: Historically, Western Australia has dominated gold production, but Victoria is reclaiming its status with significant discoveries [5][13] Project Highlights - **Sunday Creek Project**: - High-grade gold and antimony deposit with a recoverable value where antimony constitutes about 20% [6][28] - Ongoing drilling program with plans to increase from 9 to 22 rigs over the next year [5][6] - Exploration target upgraded to 2.2 to 3.2 million ounces at grades between 8.3 and 10.6 grams gold equivalent [17][18] Financial Metrics - **Funding**: The company is well-funded with $165 million allocated for a 200-kilometer drill program [7][21] - **Shareholder Composition**: 30% of shares held by ultra-high net worth individuals and 25% by institutions, indicating strong investor confidence [8][10] Strategic Plans - **Pathway to Production**: The company is focused on de-risking the project through permitting and drilling, with a decline planned to expedite drilling [22][30] - **Regional Exploration**: $20 million allocated for regional exploration to enhance resource value [23] Market Position - **Unique Asset**: The combination of high-grade gold and significant antimony content positions the project as a rare asset in a tier-one jurisdiction [29][30] - **Government Support**: Victoria has permitted four mines in the last six months, showcasing a favorable regulatory environment for mining [19][20] Technical Aspects - **Metallurgy**: The project features a simple flow sheet with over 80% free gold, producing a marketable antimony-gold concentrate [27][28] - **Drilling Success**: Recent drilling has shown increasing grades and widths, with a median width of over 2 meters for mineralized structures [25][24] Conclusion - **Investment Opportunity**: Southern Cross Gold Consolidated presents a compelling investment case with a strong management team, supportive shareholders, and a clear pathway to production in a revitalized mining jurisdiction [30]